raloxifene hydrochloride has been researched along with Pheochromocytoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doshida, M; Du, B; Igarashi, H; Kawagoe, J; Kurachi, H; Mori-Abe, A; Ohishi, A; Ohmichi, M; Ohshima, C; Ohta, T; Saitoh, M; Takahashi, K; Takahashi, T; Tezuka, N | 1 |
1 other study(ies) available for raloxifene hydrochloride and Pheochromocytoma
| Article | Year |
|---|---|
Both estrogen and raloxifene protect against beta-amyloid-induced neurotoxicity in estrogen receptor alpha-transfected PC12 cells by activation of telomerase activity via Akt cascade.
Topics: Amyloid beta-Peptides; Blotting, Western; Brain; Cell Line, Tumor; Enzyme Activation; Estrogens; Humans; Neurodegenerative Diseases; Pheochromocytoma; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Raloxifene Hydrochloride; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; Selective Estrogen Receptor Modulators; Telomerase; Transfection | 2004 |